{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:56:15Z","timestamp":1793361375676,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["20141208"],"award-info":[{"award-number":["20141208"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","award":["20121211"],"award-info":[{"award-number":["20121211"]}],"id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARG501466"],"award-info":[{"award-number":["AARG501466"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009408","name":"Brain Canada","doi-asserted-by":"crossref","award":["AARG501466"],"award-info":[{"award-number":["AARG501466"]}],"id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-159711"],"award-info":[{"award-number":["PJT-159711"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alzheimer's Research UK"},{"name":"Heart and Stroke Foundation Canadian Partnership for Stroke Recovery"},{"name":"LC Campbell Cognitive Neurology Unit"},{"name":"Sunnybrook Health Sciences Centre Department of Psychiatry"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The antihypertensive angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) have similar indications and mechanisms of action, but prior work suggests divergence in their effects on cognition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants in the National Alzheimer\u2019s Coordinating Center database with a clinical diagnosis of dementia due to Alzheimer\u2019s disease (AD) using an ACE-I or an ARB at any visit were selected. The primary outcome was delayed recall memory on the Wechsler Memory Scale Revised \u2013 Logical Memory IIA. Other cognitive domains were explored, including attention and psychomotor processing speed (Trail Making Test [TMT]-A and Digit Symbol Substitution Test [DSST]), executive function (TMT-B), and language and semantic verbal fluency (Animal Naming, Vegetable Naming, and Boston Naming Tests). Random slopes mixed-effects models with inverse probability of treatment weighting were used, yielding rate ratios (RR) or regression coefficients (B), as appropriate to the distribution of the data. Apolipoprotein (\n                      <jats:italic>APOE)<\/jats:italic>\n                      \u03b54 status and blood-brain barrier (BBB) penetrance were investigated as effect modifiers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1689 participants with AD, ARB use (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009578) was associated with 9.4% slower decline in delayed recall performance over a mean follow-up of 2.28\u2009years compared with ACE-I use (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091111) [RR\u2009=\u20091.094,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0327]; specifically, users of BBB-crossing ARBs (RR\u2009=\u20091.25,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), BBB-crossing ACE-Is (RR\u2009=\u20091.16,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010), and non-BBB-crossing ARBs (RR\u2009=\u20091.20,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) had better delayed recall performance over time compared with non-BBB-crossing ACE-I users. An interaction with\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 status (drug \u00d7\n                      <jats:italic>APOE<\/jats:italic>\n                      \u00d7 time RR\u2009=\u20091.196,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033) emerged; ARBs were associated with better delayed recall scores over time than ACE-Is in non-carriers (RR\u2009=\u20091.200,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), but not in carriers (RR\u2009=\u20091.003,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.957). ARB use was also associated with better performance over time on the TMT-A (\n                      <jats:italic>B<\/jats:italic>\n                      \u00a0=\u20092.023\u2009s,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0004) and the DSST (\n                      <jats:italic>B<\/jats:italic>\n                      \u2009=\u20090.573 symbols,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0485), and these differences were significant among\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 non-carriers (\n                      <jats:italic>B<\/jats:italic>\n                      \u2009=\u20094.066\u2009s,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0004; and\n                      <jats:italic>B<\/jats:italic>\n                      \u2009=\u20090.982 symbols,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0230; respectively). Some differences were seen also in language and verbal fluency among\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 non-carriers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Among\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 non-carriers with AD, ARB use was associated with greater preservation of memory and attention\/psychomotor processing speed, particularly compared to ACE-Is that do not cross the blood-brain-barrier.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-021-00778-8","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T09:13:07Z","timestamp":1613034787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer\u2019s disease: the importance of blood-brain barrier penetration and APOE \u03b54 carrier status"],"prefix":"10.1186","volume":"13","author":[{"given":"Michael","family":"Ouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi D.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Masellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0030-8908","authenticated-orcid":false,"given":"Walter","family":"Swardfager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"778_CR1","first-page":"1","volume":"133","author":"T Nwankwo","year":"2013","unstructured":"Nwankwo T, Yoon SSU, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011\u20132012. NCHS Data Brief. 2013;133:1\u20138.","journal-title":"NCHS Data Brief"},{"issue":"11","key":"778_CR2","doi-asserted-by":"publisher","first-page":"e008888","DOI":"10.1161\/JAHA.118.008888","volume":"7","author":"SK Dorans","year":"2020","unstructured":"Dorans SK, Mills KT, Liu Y, He J. Trends in prevalence and control of hypertension according to the 2017 American College of Cardiology\/American Heart Association (ACC\/AHA) Guideline. J Am Heart Assoc. 2020;7(11):e008888. Available from: https:\/\/doi.org\/10.1161\/JAHA.118.008888","journal-title":"J Am Heart Assoc"},{"issue":"9009","key":"778_CR3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","volume":"347","author":"I Skoog","year":"1996","unstructured":"Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S, Palmertz B, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141\u20135. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(96)90608-X\/abstract","journal-title":"Lancet"},{"issue":"3","key":"778_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/ijms17030347","volume":"17","author":"M Perrotta","year":"2016","unstructured":"Perrotta M, Lembo G, Carnevale D. Hypertension and dementia: epidemiological and experimental evidence revealing a detrimental relationship. Int J Mol Sci. 2016;17(3):347. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27005613","journal-title":"Int J Mol Sci"},{"issue":"4","key":"778_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/1756285609103483","volume":"2","author":"SP Kennelly","year":"2009","unstructured":"Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and dementia - a comprehensive review. Ther Adv Neurol Disord. 2009;2(4):241\u201360. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21179532","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"778_CR6","first-page":"e67","volume":"68","author":"C Iadecola","year":"2016","unstructured":"Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertens (Dallas, Tex 1979). 2016;68(6):e67\u201394. 2016\/10\/10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27977393","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"778_CR7","doi-asserted-by":"crossref","unstructured":"Saxby BK, Harrington F, McKeith IG, Wesnes K, Ford GA. Effects of hypertension on attention, memory, and executive function in older adults. Vol. 22, Health Psychology. Ford, Gary A.: Wolfson Unit of Clinical Pharmacology, University of Newcastle upon Tyne, Claremont Place, Newcastle upon Tyne, United Kingdom, NE2 4HH, g.a.ford@ncl.ac.uk: American Psychological Association; 2003. p. 587\u201391.","DOI":"10.1037\/0278-6133.22.6.587"},{"issue":"6","key":"778_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11906-013-0398-4","volume":"15","author":"D G\u0105secki","year":"2013","unstructured":"G\u0105secki D, Kwarciany M, Nyka W, Narkiewicz K. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep. 2013;15(6):547\u201358. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24146223","journal-title":"Curr Hypertens Rep"},{"issue":"7","key":"778_CR9","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1177\/0271678X16667364","volume":"37","author":"M Wiesmann","year":"2016","unstructured":"Wiesmann M, Roelofs M, van der Lugt R, Heerschap A, Kiliaan AJ, Claassen JAHR. Angiotensin II, hypertension and angiotensin II receptor antagonism: roles in the behavioural and brain pathology of a mouse model of Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2016;37(7):2396\u2013413. Available from: https:\/\/doi.org\/10.1177\/0271678X16667364","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"778_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.119.12892","volume":"74","author":"DLK de Jong","year":"2019","unstructured":"de Jong DLK, de Heus RAA, Rijpma A, Donders R, Olde Rikkert MGM, G\u00fcnther M, et al. Effects of nilvadipine on cerebral blood flow in patients with Alzheimer disease. Hypertension. 2019;74(2):413\u201320. Available from: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.12892","journal-title":"Hypertension"},{"issue":"6","key":"778_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"JD Williamson","year":"2019","unstructured":"SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553\u201361. Available from: https:\/\/doi.org\/10.1001\/jama.2018.21442","journal-title":"JAMA"},{"issue":"1","key":"778_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","volume":"19","author":"J Ding","year":"2020","unstructured":"Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, et al. Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19(1):61\u201370. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S147444221930393X","journal-title":"Lancet Neurol"},{"issue":"9","key":"778_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ajh.2009.119","volume":"22","author":"E Duron","year":"2009","unstructured":"Duron E, Rigaud A-S, Dubail D, Mehrabian S, Latour F, Seux M-L, et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer\u2019s disease. Am J Hypertens. 2009;22(9):1020\u20134. Available from: https:\/\/doi.org\/10.1038\/ajh.2009.119","journal-title":"Am J Hypertens"},{"issue":"10113","key":"778_CR14","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"G Livingston","year":"2017","unstructured":"Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673\u2013734. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(17)31363-6","journal-title":"Lancet"},{"issue":"10","key":"778_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0b013e3182a35228","volume":"81","author":"S Yasar","year":"2013","unstructured":"Yasar S, Xia J, Yao W, Furberg CD, Xue Q-L, Mercado CI, et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896\u2013903. 2013\/08\/02. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23911756","journal-title":"Neurology"},{"issue":"3","key":"778_CR16","doi-asserted-by":"publisher","first-page":"e267 LP","DOI":"10.1212\/WNL.0000000000008732","volume":"94","author":"R Peters","year":"2020","unstructured":"Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H, et al. Investigation of antihypertensive class, dementia, and cognitive decline. Neurology. 2020;94(3):e267 LP\u2013e281. Available from: http:\/\/n.neurology.org\/content\/94\/3\/e267.abstract","journal-title":"Neurology"},{"issue":"10","key":"778_CR17","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1212\/WNL.0b013e3182a351d4","volume":"81","author":"RP Gelber","year":"2013","unstructured":"Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, White LR. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013;81(10):888\u201395. 2013\/08\/02. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23911753","journal-title":"Neurology"},{"key":"778_CR18","doi-asserted-by":"publisher","first-page":"4368474","DOI":"10.1155\/2017\/4368474","volume":"2017","author":"G Xu","year":"2017","unstructured":"Xu G, Bai F, Lin X, Wang Q, Wu Q, Sun S, et al. Association between antihypertensive drug use and the incidence of cognitive decline and dementia: a meta-analysis of prospective cohort studies. Biomed Res Int. 2017;2017:4368474. Capurso C, editor. Available from: https:\/\/doi.org\/10.1155\/2017\/4368474","journal-title":"Biomed Res Int"},{"issue":"5","key":"778_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41440-018-0167-5","volume":"42","author":"T Ohtsubo","year":"2019","unstructured":"Ohtsubo T, Shibata R, Kai H, Okamoto R, Kumagai E, Kawano H, et al. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis. Hypertens Res. 2019;42(5):641\u20139. Available from: https:\/\/doi.org\/10.1038\/s41440-018-0167-5","journal-title":"Hypertens Res"},{"issue":"8","key":"778_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/ajhp\/58.8.671","volume":"58","author":"JE Rodgers","year":"2001","unstructured":"Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Heal Pharm. 2001;58(8):671\u201383. Available from: https:\/\/doi.org\/10.1093\/ajhp\/58.8.671","journal-title":"Am J Heal Pharm"},{"issue":"9","key":"778_CR21","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/jgs.12415","volume":"61","author":"ME Soto","year":"2013","unstructured":"Soto ME, van Kan GA, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, et al. Angiotensin-converting enzyme inhibitors and Alzheimer\u2019s disease progression in older adults: results from the R\u00e9seau sur la Maladie d\u2019Alzheimer Fran\u00e7ais cohort. J Am Geriatr Soc. 2013;61(9):1482\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"778_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/gps.1523","volume":"21","author":"L Rozzini","year":"2006","unstructured":"Rozzini L, Chilovi BV, Bertoletti E, Conti M, Del Rio I, Trabucchi M, et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry. 2006;21(6):550\u20135.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"778_CR23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/HJH.0000000000000086","volume":"32","author":"W-C Chiu","year":"2014","unstructured":"Chiu W-C, Ho W-C, Lin M-H, Lee H-H, Yeh Y-C, Wang J-D, et al. Angiotension receptor blockers reduce the risk of dementia. J Hypertens. 2014;32(4):938\u201347.","journal-title":"J Hypertens"},{"key":"778_CR24","doi-asserted-by":"crossref","unstructured":"Li ECK, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;(8) Available from: https:\/\/doi.org\/\/10.1002\/14651858.CD009096.pub2","DOI":"10.1002\/14651858.CD009096.pub2"},{"issue":"3","key":"778_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3233\/JAD-170238","volume":"59","author":"JD Edwards","year":"2017","unstructured":"Edwards JD, Ramirez J, Callahan BL, Tobe SW, Oh P, Berezuk C, et al. Antihypertensive treatment is associated with MRI-derived markers of neurodegeneration and impaired cognition: a propensity-weighted cohort study. J Alzheimers Dis. 2017;59(3):1113\u201322.","journal-title":"J Alzheimers Dis"},{"key":"778_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3233\/JAD-180943","volume":"68","author":"C Moran","year":"2019","unstructured":"Moran C, Xie K, Poh S, Chew S, Beare R, Wang W, et al. Observational study of brain atrophy and cognitive decline comparing a sample of community-dwelling people taking angiotensin converting enzyme inhibitors and angiotensin receptor blockers over time. J Alzheimers Dis. 2019;68:1479\u201388.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"778_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bcp.12511","volume":"79","author":"KL Goh","year":"2015","unstructured":"Goh KL, Bhaskaran K, Minassian C, Evans SJW, Smeeth L, Douglas IJ. Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink. Br J Clin Pharmacol. 2015;79(2):337\u201350. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25223602","journal-title":"Br J Clin Pharmacol"},{"key":"778_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JAD-190362","volume":"70","author":"J Bohlken","year":"2019","unstructured":"Bohlken J, Jacob L, Kostev K. The relationship between the use of antihypertensive drugs and the incidence of dementia in general practices in Germany. J Alzheimers Dis. 2019;70:91\u20137.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"778_CR29","doi-asserted-by":"publisher","first-page":"e0206705","DOI":"10.1371\/journal.pone.0206705","volume":"13","author":"D Barthold","year":"2018","unstructured":"Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J. The association of multiple anti-hypertensive medication classes with Alzheimer\u2019s disease incidence across sex, race, and ethnicity. PLoS One. 2018;13(11):e0206705. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30383807","journal-title":"PLoS One"},{"issue":"1","key":"778_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-017-0255-9","volume":"9","author":"JK Ho","year":"2017","unstructured":"Ho JK, Nation DA. Memory is preserved in older adults taking AT1 receptor blockers. Alzheimers Res Ther. 2017;9(1):1\u201314.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"778_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/gerona\/60.1.67","volume":"60","author":"I Hajjar","year":"2005","unstructured":"Hajjar I, Catoe H, Sixta S, Boland R, Johnson D, Hirth V, et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci. 2005;60(1):67\u201373.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"778_CR32","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1001\/archneurol.2012.1010","volume":"69","author":"I Hajjar","year":"2012","unstructured":"Hajjar I, Brown L, Mack WJ, Chui H. Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol. 2012;69(12):1632\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22964777","journal-title":"Arch Neurol"},{"key":"778_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.dadm.2016.02.007","volume":"2","author":"L Glodzik","year":"2016","unstructured":"Glodzik L, Rusinek H, Kamer A, Pirraglia E, Tsui W, Mosconi L, et al. Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects. Alzheimers Dement (Amsterdam, Netherlands). 2016;2:95\u2013104. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27239540","journal-title":"Alzheimers Dement (Amsterdam, Netherlands)"},{"issue":"3","key":"778_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/WAD.0b013e318142774e","volume":"21","author":"DL Beekly","year":"2007","unstructured":"Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, et al. The National Alzheimer\u2019s Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord. 2007;21(3):249\u201358.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"778_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jamda.2018.08.002","volume":"20","author":"PJ Tully","year":"2019","unstructured":"Tully PJ, Helmer C, Peters R, Tzourio C. Exploiting drug-apolipoprotein E gene interactions in hypertension to preserve cognitive function: the 3-city cohort study. J Am Med Dir Assoc. 2019;20(2):188\u2013194.e4. Available from: https:\/\/doi.org\/10.1016\/j.jamda.2018.08.002","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"778_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-150487","volume":"50","author":"DA Nation","year":"2016","unstructured":"Nation DA, Ho J, Yew B, Initiative ADN. Older adults taking AT1-receptor blockers exhibit reduced cerebral amyloid retention. J Alzheimers Dis. 2016;50(3):779\u201389. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26757036","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"778_CR37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology."},{"issue":"3","key":"778_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJ, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"778_CR39","first-page":"62","volume":"298","author":"P Gohlke","year":"2001","unstructured":"Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, et al. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther. 2001;298(1):62\u201370.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"778_CR40","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/00004872-200205000-00026","volume":"20","author":"P Gohlke","year":"2002","unstructured":"Gohlke P, Von K\u00fcgelgen S, J\u00fcrgensen T, Kox T, Rascher W, Culman J, et al. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J Hypertens. 2002;20(5):909\u201318.","journal-title":"J Hypertens"},{"issue":"5","key":"778_CR41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1185\/030079903125001974","volume":"19","author":"T Unger","year":"2003","unstructured":"Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr Med Res Opin. 2003;19(5):449\u201351. Available from: https:\/\/doi.org\/10.1185\/030079903125001974","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"778_CR42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ajh\/2.4.294","volume":"2","author":"DW Cushman","year":"1989","unstructured":"Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989;2(4):294\u2013306.","journal-title":"Am J Hypertens"},{"issue":"12","key":"778_CR43","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/0028-3908(95)00146-8","volume":"34","author":"S Jouquey","year":"1995","unstructured":"Jouquey S, Mathieu MN, Hamon G, Chevillard C. Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats. Neuropharmacology. 1995;34(12):1689\u201392.","journal-title":"Neuropharmacology."},{"issue":"3","key":"778_CR44","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1046\/j.1471-4159.1997.68031304.x","volume":"68","author":"TA Jenkins","year":"1997","unstructured":"Jenkins TA, Mendelsohn FA, Chai SY. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J Neurochem. 1997;68(3):1304\u201311.","journal-title":"J Neurochem"},{"issue":"2 Pt 1","key":"778_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.amjhyper.2004.09.004","volume":"18","author":"J Tan","year":"2005","unstructured":"Tan J, Wang JM, Leenen FHH. Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats. Am J Hypertens. 2005;18(2 Pt 1):158\u201364.","journal-title":"Am J Hypertens"},{"key":"778_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1440-1681.1992.tb02803.x","volume":"19","author":"SY Chai","year":"1992","unstructured":"Chai SY, Perich R, Jackson B, Mendelsohn FA, Johnston CI. Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme. Clin Exp Pharmacol Physiol Suppl. 1992;19:7\u201312.","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"issue":"Suppl 4","key":"778_CR47","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/00005344-198900000-00008","volume":"14","author":"P Gohlke","year":"1989","unstructured":"Gohlke P, Sch\u00f6lkens B, Henning R, Urbach H, Unger T. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288. J Cardiovasc Pharmacol. 1989;14(Suppl 4):S32\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"key":"778_CR48","doi-asserted-by":"publisher","first-page":"b5465","DOI":"10.1136\/bmj.b5465","volume":"340","author":"N-C Li","year":"2010","unstructured":"Li N-C, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20068258","journal-title":"BMJ"},{"issue":"13","key":"778_CR49","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/archinternmed.2009.175","volume":"169","author":"KM Sink","year":"2009","unstructured":"Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the cardiovascular Health Study. Arch Intern Med. 2009;169(13):1195\u2013202. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19597068","journal-title":"Arch Intern Med"},{"issue":"7","key":"778_CR50","doi-asserted-by":"publisher","first-page":"1324 LP","DOI":"10.1212\/01.WNL.0000140705.23869.E9","volume":"63","author":"T Ohrui","year":"2004","unstructured":"Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004;63(7):1324 LP\u20131325. Available from: http:\/\/n.neurology.org\/content\/63\/7\/1324.abstract","journal-title":"Neurology"},{"key":"778_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-1-4613-0555-2_3","volume-title":"The Wechsler memory scale\u2014revised BT - advances in psychological assessment: volume 7","author":"GJ Chelune","year":"1990","unstructured":"Chelune GJ, Bornstein RA, Prifitera A. The Wechsler memory scale\u2014revised BT - advances in psychological assessment: volume 7. In: McReynolds P, Rosen JC, Chelune GJ, editors. Boston: Springer US; 1990. p. 65\u201399. Available from: https:\/\/doi.org\/10.1007\/978-1-4613-0555-2_3."},{"issue":"4","key":"778_CR52","doi-asserted-by":"publisher","first-page":"a006171","DOI":"10.1101\/cshperspect.a006171","volume":"2","author":"S Weintraub","year":"2012","unstructured":"Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(4):a006171. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22474609","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"Pt 3","key":"778_CR53","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/brain\/awl385","volume":"130","author":"BR Reed","year":"2007","unstructured":"Reed BR, Mungas DM, Kramer JH, Ellis W, Vinters HV, Zarow C, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer\u2019s disease and cerebrovascular disease. Brain. 2007;130(Pt 3):731\u20139.","journal-title":"Brain."},{"key":"778_CR54","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1007\/978-1-4419-1005-9_1538","volume-title":"Trail-Making Test BT - Encyclopedia of Behavioral Medicine","author":"RS Bucks","year":"2013","unstructured":"Bucks RS. Trail-Making Test BT - Encyclopedia of Behavioral Medicine. In: Gellman MD, Turner JR, editors. . New York: Springer New York; 2013. p. 1986\u20137. Available from: https:\/\/doi.org\/10.1007\/978-1-4419-1005-9_1538."},{"key":"778_CR55","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1007\/978-0-387-79948-3_4122","volume-title":"WAIS-R BT - Encyclopedia of Clinical Neuropsychology","year":"2011","unstructured":"Kreutzer JS, DeLuca J, Caplan B, editors. WAIS-R BT - Encyclopedia of Clinical Neuropsychology. New York: Springer New York; 2011. p. 2668. Available from: https:\/\/doi.org\/10.1007\/978-0-387-79948-3_4122"},{"issue":"9","key":"778_CR56","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","volume":"39","author":"JC Morris","year":"1989","unstructured":"Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer\u2019s disease. Neurology. 1989;39(9):1159\u201365.","journal-title":"Neurology."},{"key":"778_CR57","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/978-0-387-79948-3_869","volume-title":"Boston Naming Test BT - Encyclopedia of Clinical Neuropsychology","author":"C Roth","year":"2011","unstructured":"Roth C. Boston Naming Test BT - Encyclopedia of Clinical Neuropsychology. In: Kreutzer JS, DeLuca J, Caplan B, editors. . New York: Springer New York; 2011. p. 430\u20133. Available from: https:\/\/doi.org\/10.1007\/978-0-387-79948-3_869."},{"key":"778_CR58","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Rubio V. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition). J Stat Software. 2017;1 B Rev 2 [Internet]. Available from: https:\/\/www.jstatsoft.org\/v077\/b02","DOI":"10.18637\/jss.v077.b02"},{"key":"778_CR59","doi-asserted-by":"crossref","unstructured":"Brooks ME, Kristensen K, Van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R J. 2017;9(2):378\u2013400.","DOI":"10.32614\/RJ-2017-066"},{"key":"778_CR60","unstructured":"van der Wal WM, Geskus RB. ipw: an R package for inverse probability weighting. J Stat Software. 2011;1(13) Available from: https:\/\/www.jstatsoft.org\/v043\/i13"},{"issue":"6","key":"778_CR61","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206\u201352. Available from: https:\/\/doi.org\/10.1161\/01.HYP.0000107251.49515.c2","journal-title":"Hypertension"},{"issue":"5","key":"778_CR62","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320. Available from: https:\/\/doi.org\/10.1001\/jama.2013.284427","journal-title":"JAMA"},{"issue":"19","key":"778_CR63","doi-asserted-by":"publisher","first-page":"e127 LP","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127 LP\u2013e248. Available from: http:\/\/www.onlinejacc.org\/content\/71\/19\/e127.abstract","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"778_CR64","doi-asserted-by":"publisher","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"PB Verghese","year":"2013","unstructured":"Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, et al. ApoE influences amyloid-\u03b2 (A\u03b2) clearance despite minimal apoE\/A\u03b2 association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110(19):E1807\u201316. 2013\/04\/25. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23620513","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"778_CR65","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","volume":"96","author":"C-C Liu","year":"2017","unstructured":"Liu C-C, Zhao N, Fu Y, Wang N, Linares C, Tsai C-W, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96(5):1024\u20131032.e3. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29216449","journal-title":"Neuron"},{"issue":"2","key":"778_CR66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3233\/JAD-140024","volume":"41","author":"L Nelson","year":"2014","unstructured":"Nelson L, Gard P, Tabet N. Hypertension and inflammation in Alzheimer\u2019s disease: close partners in disease development and progression! J Alzheimers Dis. 2014;41(2):331\u201343.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"778_CR67","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/hr.2014.51","volume":"37","author":"AU Hasan","year":"2014","unstructured":"Hasan AU, Ohmori K, Hashimoto T, Kamitori K, Yamaguchi F, Ishihara Y, et al. Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity. Hypertens Res. 2014;37(7):621\u20138. Available from: https:\/\/doi.org\/10.1038\/hr.2014.51","journal-title":"Hypertens Res"},{"issue":"2","key":"778_CR68","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s12035-017-0450-5","volume":"55","author":"R Goel","year":"2018","unstructured":"Goel R, Bhat SA, Hanif K, Nath C, Shukla R. Angiotensin II receptor blockers attenuate lipopolysaccharide-induced memory impairment by modulation of NF-\u03baB-mediated BDNF\/CREB expression and apoptosis in spontaneously hypertensive rats. Mol Neurobiol. 2018;55(2):1725\u201339.","journal-title":"Mol Neurobiol"},{"key":"778_CR69","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fphar.2018.00440","volume":"9","author":"AK Gebre","year":"2018","unstructured":"Gebre AK, Altaye BM, Atey TM, Tuem KB, Berhe DF. Targeting renin-angiotensin system against Alzheimer\u2019s disease. Front Pharmacol. 2018;9:440.","journal-title":"Front Pharmacol"},{"issue":"3","key":"778_CR70","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s13311-019-00723-6","volume":"16","author":"HJ Drews","year":"2019","unstructured":"Drews HJ, Yenkoyan K, Lourhmati A, Buadze M, Kabisch D, Verleysdonk S, et al. Intranasal losartan decreases perivascular beta amyloid, inflammation, and the decline of neurogenesis in hypertensive rats. Neurotherapeutics. 2019;16(3):725\u201340. Available from: https:\/\/doi.org\/10.1007\/s13311-019-00723-6","journal-title":"Neurotherapeutics."},{"issue":"11","key":"778_CR71","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1172\/JCI31547","volume":"117","author":"J Wang","year":"2007","unstructured":"Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007;117(11):3393\u2013402. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17965777","journal-title":"J Clin Invest"},{"issue":"2\u20133","key":"778_CR72","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/rej.2009.0944","volume":"13","author":"L Danielyan","year":"2010","unstructured":"Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, et al. Protective effects of intranasal losartan in the APP\/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 2010;13(2\u20133):195\u2013201. Available from: https:\/\/doi.org\/10.1089\/rej.2009.0944","journal-title":"Rejuvenation Res"},{"issue":"2","key":"778_CR73","first-page":"151","volume":"4","author":"L Ferrington","year":"2012","unstructured":"Ferrington L, Palmer LE, Love S, Horsburgh KJ, Kelly PA, Kehoe PG. Angiotensin II-inhibition: effect on Alzheimer\u2019s pathology in the aged triple transgenic mouse. Am J Transl Res. 2012;4(2):151\u201364. 2012\/04\/12. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22611468","journal-title":"Am J Transl Res"},{"issue":"45","key":"778_CR74","doi-asserted-by":"publisher","first-page":"37644","DOI":"10.1074\/jbc.M508460200","volume":"280","author":"ML Hemming","year":"2005","unstructured":"Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280(45):37644\u201350. 2005\/09\/09. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16154999","journal-title":"J Biol Chem"},{"issue":"32","key":"778_CR75","doi-asserted-by":"publisher","first-page":"8628 LP","DOI":"10.1523\/JNEUROSCI.1549-07.2007","volume":"27","author":"K Zou","year":"2007","unstructured":"Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, et al. Angiotensin-converting enzyme converts amyloid \u03b2-protein 1\u201342 (A\u03b2<sub>1\u201342<\/sub>) to A\u03b2<sub>1\u201340<\/sub>, and its inhibition enhances brain A\u03b2 deposition. J Neurosci. 2007;27(32):8628 LP\u2013635. Available from: http:\/\/www.jneurosci.org\/content\/27\/32\/8628.abstract","journal-title":"J Neurosci"},{"issue":"32","key":"778_CR76","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1523\/JNEUROSCI.1549-07.2007","volume":"27","author":"K Zou","year":"2007","unstructured":"Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci. 2007;27(32):8628\u201335.","journal-title":"J Neurosci"},{"issue":"6","key":"778_CR77","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.ajpath.2013.01.053","volume":"182","author":"K Zou","year":"2013","unstructured":"Zou K, Liu J, Watanabe A, Hiraga S, Liu S, Tanabe C, et al. A\u03b243 is the earliest-depositing A\u03b2 species in APP transgenic mouse brain and is converted to A\u03b241 by two active domains of ACE. Am J Pathol. 2013;182(6):2322\u201331.","journal-title":"Am J Pathol"},{"issue":"1","key":"778_CR78","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.nbd.2007.01.004","volume":"26","author":"ML Hemming","year":"2007","unstructured":"Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis. 2007;26(1):273\u201381.","journal-title":"Neurobiol Dis"},{"key":"778_CR79","doi-asserted-by":"crossref","unstructured":"Liu S, Ando F, Fujita Y, Liu J, Maeda T, Shen X, et al. A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer\u2019s disease pathology in mice. J Biol Chem. 2019 ;294(25):9760\u20139770. 2019\/05\/09. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31072831","DOI":"10.1074\/jbc.RA118.006420"},{"issue":"41","key":"778_CR80","doi-asserted-by":"publisher","first-page":"30471","DOI":"10.1074\/jbc.M605827200","volume":"281","author":"EA Eckman","year":"2006","unstructured":"Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem. 2006;281(41):30471\u20138.","journal-title":"J Biol Chem"},{"key":"778_CR81","doi-asserted-by":"crossref","unstructured":"Burnham SC, Laws SM, Budgeon CA, Dor\u00e9 V, Porter T, Bourgeat P, et al. Impact of APOE-\u03b54 carriage on the onset and rates of neocortical A\u03b2-amyloid deposition. Neurobiol Aging. 2020; Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0197458020301871","DOI":"10.1016\/j.neurobiolaging.2020.06.001"},{"issue":"5","key":"778_CR82","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/ana.25228","volume":"83","author":"KB Rajan","year":"2018","unstructured":"Rajan KB, Barnes LL, Wilson RS, Weuve J, McAninch EA, Evans DA. Blood pressure and risk of incident Alzheimer\u2019s disease dementia by antihypertensive medications and APOE \u03b54 allele. Ann Neurol. 2018;83(5):935\u201344. 2018\/05\/11. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29637601","journal-title":"Ann Neurol"},{"issue":"11","key":"778_CR83","doi-asserted-by":"publisher","first-page":"e0224975","DOI":"10.1371\/journal.pone.0224975","volume":"14","author":"IY Kim","year":"2019","unstructured":"Kim IY, Grodstein F, Kraft P, Curhan GC, Hughes KC, Huang H, et al. Interaction between apolipoprotein E genotype and hypertension on cognitive function in older women in the Nurses\u2019 Health Study. PLoS One. 2019;14(11):e0224975. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0224975","journal-title":"PLoS One"},{"key":"778_CR84","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2174\/1567205014666171016101816","volume":"15","author":"FF de Oliveira","year":"2018","unstructured":"de Oliveira FF, Chen ES, Bertolucci MCS, PHF. Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer&#39;s disease Dementia. Curr Alzheimer Res. 2018;15:386\u201398. Available from: http:\/\/www.eurekaselect.com\/node\/156397\/article","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"778_CR85","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1385\/JMN:30:3:267","volume":"30","author":"B Wang","year":"2006","unstructured":"Wang B, Jin F, Yang Z, Lu Z, Kan R, Li S, et al. The insertion polymorphism in angiotensin-converting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease. J Mol Neurosci. 2006;30(3):267\u201371.","journal-title":"J Mol Neurosci"},{"key":"778_CR86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2020.12.011","volume":"100","author":"M Ouk","year":"2021","unstructured":"Ouk M, Wu C-Y, Rabin JS, Edwards JD, Ramirez J, Masellis M, et al. Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Neurobiol Aging. 2021;100:22\u201331. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S019745802030422X","journal-title":"Neurobiol Aging"},{"key":"778_CR87","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jacc.2016.01.007","volume":"67","author":"W Swardfager","year":"2016","unstructured":"Swardfager W, Black SE. Coronary artery calcification: a canary in the cognitive coalmine. J Am Coll Cardiol. 2016;67:1023\u20136. United States","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"778_CR88","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s11064-011-0481-7","volume":"36","author":"JF Lucatelli","year":"2011","unstructured":"Lucatelli JF, Barros AC, da Silva VK, da Silva Machado F, Constantin PC, Dias AAC, et al. Genetic influences on Alzheimer\u2019s disease: evidence of interactions between the genes APOE, APOC1 and ACE in a sample population from the south of Brazil. Neurochem Res. 2011;36(8):1533\u20139. Available from: http:\/\/europepmc.org\/abstract\/MED\/21533863","journal-title":"Neurochem Res"},{"issue":"3","key":"778_CR89","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3233\/JAD-131694","volume":"40","author":"R O\u2019Caoimh","year":"2014","unstructured":"O\u2019Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, et al. Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer\u2019s disease. J Alzheimers Dis. 2014;40(3):595\u2013603.","journal-title":"J Alzheimers Dis"},{"key":"778_CR90","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.brainres.2011.09.016","volume":"1421","author":"K Yamada","year":"2011","unstructured":"Yamada K, Horita T, Takayama M, Takahashi S. Effect of a centrally active angiotensin converting enzyme inhibitor , perindopril , on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res. 2011;1421:110\u201320. Available from: https:\/\/doi.org\/10.1016\/j.brainres.2011.09.016","journal-title":"Brain Res"},{"issue":"1\u20132","key":"778_CR91","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0361-9230(93)90036-B","volume":"30","author":"Z Li","year":"1993","unstructured":"Li Z, Bains JS, Ferguson AV. Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res Bull. 1993;30(1\u20132):33\u20139.","journal-title":"Brain Res Bull"},{"issue":"1","key":"778_CR92","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0014-2999(92)90593-S","volume":"219","author":"JD Bui","year":"1992","unstructured":"Bui JD, Kimura B, Ian PM. Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier. Eur J Pharmacol. 1992;219(1):147\u201351. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/001429999290593S","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"778_CR93","doi-asserted-by":"publisher","first-page":"e0201719","DOI":"10.1371\/journal.pone.0201719","volume":"13","author":"RJ Hazlewood","year":"2018","unstructured":"Hazlewood RJ, Chen Q, Clark FK, Kuchtey J, Kuchtey RW. Differential effects of angiotensin II type I receptor blockers on reducing intraocular pressure and TGF\u03b2 signaling in the mouse retina. PLoS One. 2018;13(8):e0201719. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0201719","journal-title":"PLoS One"},{"issue":"3","key":"778_CR94","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/ajh\/hpu197","volume":"28","author":"S Villapol","year":"2014","unstructured":"Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens. 2014;28(3):289\u201399. Available from: https:\/\/doi.org\/10.1093\/ajh\/hpu197","journal-title":"Am J Hypertens"},{"issue":"8","key":"778_CR95","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.nucmedbio.2012.06.012","volume":"39","author":"A Noda","year":"2012","unstructured":"Noda A, Fushiki H, Murakami Y, Sasaki H, Miyoshi S, Kakuta H, et al. Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques. Nucl Med Biol. 2012;39(8):1232\u20135.","journal-title":"Nucl Med Biol"},{"issue":"6","key":"778_CR96","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.nucmedbio.2012.01.008","volume":"39","author":"K Shimizu","year":"2012","unstructured":"Shimizu K, Takashima T, Yamane T, Sasaki M, Kageyama H, Hashizume Y, et al. Whole-body distribution and radiation dosimetry of [11C] telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl Med Biol. 2012;39(6):847\u201353.","journal-title":"Nucl Med Biol"},{"issue":"7806","key":"778_CR97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood\u2013brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71\u20136. Available from: https:\/\/doi.org\/10.1038\/s41586-020-2247-3","journal-title":"Nature"},{"issue":"9","key":"778_CR98","doi-asserted-by":"publisher","first-page":"864.e17","DOI":"10.1016\/j.jamda.2016.06.021","volume":"17","author":"K Piotrowicz","year":"2016","unstructured":"Piotrowicz K, Prejbisz A, Klocek M, Top\u00f3r-M\u0105dry R, Szczepaniak P, Kawecka-Jaszcz K, et al. Subclinical mood and cognition impairments and blood pressure control in a large cohort of elderly hypertensives. J Am Med Dir Assoc. 2016;17(9):864.e17\u201322.","journal-title":"J Am Med Dir Assoc"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00778-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00778-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00778-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T01:05:42Z","timestamp":1674954342000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00778-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00778-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As determined by the University of Washington Human Subjects Division, the NACC database itself is exempt from IRB review and approval because it does not involve human participants, as defined by federal and state regulations. However, all contributing ADCs are required to obtain informed consent from their participants and maintain their own separate IRB review and approval from their institution prior to submitting data to NACC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MO, CW, JSR, AJ, JDE, JR, MM, RHS, NH, KLL, SEB, and WS report no potential competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}